These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11110012)

  • 1. Insomnia related to biperiden withdrawal in two schizophrenic patients.
    Hirose S
    Int Clin Psychopharmacol; 2000 Nov; 15(6):357-9. PubMed ID: 11110012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dependence on anticholinergics among schizophrenics. Iatrogenic disease or self-medication?].
    Chamorro García L
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1991; 19(6):298-303. PubMed ID: 1687233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebound insomnia after abrupt clozapine withdrawal.
    Staedt J; Stoppe G; Hajak G; Ruther E
    Eur Arch Psychiatry Clin Neurosci; 1996; 246(2):79-82. PubMed ID: 9063912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
    Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of antiparkinson drug withdrawal.
    Jellinek T; Gardos G; Cole JO
    Am J Psychiatry; 1981 Dec; 138(12):1567-71. PubMed ID: 6118066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia.
    Chemerinski E; Ho BC; Flaum M; Arndt S; Fleming F; Andreasen NC
    Compr Psychiatry; 2002; 43(5):393-6. PubMed ID: 12216015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication.
    Wada Y; Koshino Y; Yamaguchi N
    Clin Neuropharmacol; 1987 Aug; 10(4):370-5. PubMed ID: 2902920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine for the treatment of tardive dyskinesia.
    Almeida OP
    J Clin Psychiatry; 1998 Jul; 59(7):380-1. PubMed ID: 9714267
    [No Abstract]   [Full Text] [Related]  

  • 9. Rebound insomnia in neuroleptic drug withdrawal neurophysiologic characteristics.
    van Sweden B
    Pharmacopsychiatry; 1987 May; 20(3):116-9. PubMed ID: 2885865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study.
    Gjerden P; Bramness JG; Slørdal L
    Br J Clin Pharmacol; 2009 Feb; 67(2):228-33. PubMed ID: 19094158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs.
    Luchins DJ; Freed WJ; Wyatt RJ
    Am J Psychiatry; 1980 Nov; 137(11):1395-8. PubMed ID: 6108078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.
    Jellinek T
    Dis Nerv Syst; 1977 May; 38(5):353-5. PubMed ID: 852367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine.
    Gjerden P; Slørdal L; Bramness JG
    Br J Clin Pharmacol; 2009 Aug; 68(2):238-42. PubMed ID: 19694744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous biperiden in akathisia: an open pilot study.
    Hirose S; Ashby CR
    Int J Psychiatry Med; 2000; 30(2):185-94. PubMed ID: 11001281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride.
    Isawa S; Murasaki M; Miura S; Yoshioka M; Uchiumi M; Kumagai Y; Aoki S; Hisazumi H; Kudo S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):111-8. PubMed ID: 10495985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential drug-drug interaction in Mexican patients with schizophrenia.
    Ocaña-Zurita MC; Juárez-Rojop IE; Genis A; Tovilla-Zárate CA; González-Castro TB; Lilia López-Narváez M; de la O de la O ME; Nicolini H
    Int J Psychiatry Clin Pract; 2016 Nov; 20(4):249-53. PubMed ID: 27552677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study.
    Liang CS; Ho PS; Shen LJ; Lee WK; Yang FW; Chiang KT
    Schizophr Res; 2010 Jun; 119(1-3):138-44. PubMed ID: 20299191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal.
    Perenyi A; Gardos G; Samu I; Kallos M; Cole JO
    Clin Neuropharmacol; 1983 Mar; 6(1):55-61. PubMed ID: 6133613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses].
    Kastrup O; Eikmeier G; Gastpar M
    Dtsch Med Wochenschr; 1991 Nov; 116(46):1748-51. PubMed ID: 1935662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic withdrawal phenomena in the medical-surgical setting.
    Dilsaver SC; Coffman JA
    Gen Hosp Psychiatry; 1988 Nov; 10(6):438-46. PubMed ID: 2904918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.